N/A N=31 Robotic and Conventional Hand Therapy After Stroke
Stroke
Primary: Impairment Based Arm Measures - Change in Upper Extremity Portion of the Fugl Meyer — 5.9; 2.1 change in units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=400 Staccato Prochlorperazine in Migraine (Out Patient)
Migraine Headache · Aura
Primary: Headache Pain Relief at 2 hr — 40; 62; 58; 68 Participants — p=0.0012
Phase 2 N=75 Staccato Prochlorperazine in Migraine (in Clinic)
Migraine Headache, With or Without Aura
Primary: Headache Pain Relief at 2 hr Post-dose by 2-point Definition — 6; 11; 13 Participants
Phase 3 N=1,578 Japan Statin Treatment Against Recurrent Stroke (J-STARS)
Ischemic Stroke
Primary: Incidence Rate of Stroke and TIA — 2.56; 2.65 events /100 person-years — p=0.8234
Phase 3 N=2,499 Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men
HIV Infections
Primary: HIV Seroconversion — 48; 83 Participants — p=0.002
N/A N=19 Effects of Robotic Versus Manually-Assisted Locomotor Training for Individuals With Incomplete Spinal Cord Injury
Spinal Cord Injuries
Primary: Self Selected Velocity on Treadmill — 0.24; 0.22; 0.4; 0.39 m/s — p=0.05
Phase 3 N=131 The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients
Colitis, Ulcerative
Primary: Induction of Clinical Remission — 44.4; 46.5 Percentage of participants
Phase 2 N=312 GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
Rheumatoid Arthritis
Primary: AUC(0-inf) of GP2013, MabThera and Rituxan Following IV Infusion in Patients With RA — 7627.44; 6896.97; 7536.89 day*mcg/mL
Phase 3 N=223 12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device
Nasal Polyps
Primary: Adverse Events — 169 Participants
N/A N=67 Follow-Up Study Evaluating The Long Term Safety and Efficacy of BST-CarGel and Microfracture Repair of the Knee
Knee Injuries
Primary: Degree of Lesion Filling (%Fill) by Repair Tissue at Degree of Lesion Filling (%Fill) by Repair Tissue at 5 Years Through MRI. — 93.79; 86.96 Percentage of lesion filled…
Phase 1 N=28 A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib
Healthy, Hepatic Insufficiency
Primary: Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf) — 1031; 758.9; 1189; 1378 nanogram*hour/milliliter (ng*hr/mL)
Phase 2 N=9 Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
IPF
Primary: Number of Participants With Respiratory and/or Hemodynamic Deteriorations — 1; 3 Participants
Phase 4 N=130 Citicoline for Bipolar 1 Disorder and Cocaine Dependence
Bipolar Disorder · Cocaine Dependence
Primary: Percentage of Participants With Presence of a Cocaine-Positive Urine Screen — 59.0; 49.2 percentage of participants
N/A N=117 Role of Cysteinyl Leukotrienes in the Pathogenesis of Asthma in Obesity
Asthma · Obesity
Primary: Plasma Leptin — 55.4; 8.9; 24.2; 46.5 ng/ml — p=<0.0001
Phase 4 N=146 A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients
Thrombocythemia, Hemorrhagic
Primary: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time — 66.4; 66.9; 0.5; -1.1 percentage of ejection fraction